Arax Advisory Partners’s Zenas BioPharma ZBIO Stock Holding History

Arax Advisory Partners’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.64K	Buy	+104	New	+$2.07K	﹤0.01%	4754
2026 Q1	–	Sell	-4	Closed	-$145	–	4433
2025 Q4	$145	Sell	4 -111	-97%	-$3.65K	﹤0.01%	3769
2025 Q3	$2.55K	Buy	+115	New	+$1.87K	﹤0.01%	3053

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $242M AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Arax Advisory Partners's ZBIO Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Zenas BioPharma (ZBIO) in Q2 2026: 104 shares worth $2.64K. The stake represents ﹤0.01% of the portfolio and ranks #4754 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in ZBIO as recently as Q4 2025.

Arax Advisory Partners first reported a position in ZBIO in Q3 2025 and has held it in 3 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

Arax Advisory Partners held 104 shares of Zenas BioPharma worth $2.64K as of Q2 2026.
Zenas BioPharma was a new Arax Advisory Partners position in Q2 2026.
Zenas BioPharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4754 holding.
Arax Advisory Partners first reported a position in Zenas BioPharma in Q3 2025 and has held it in 3 quarters since.
144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.